Keyword: Catabasis Pharmaceuticals
The reorg will cost about $1 million but will save the company about $3.3 million a year.
Catabasis is looking to test its experimental Duchenne drug edasalonexent in a late-stage trial.
The approval by the FDA last year for Sarepta’s DMD drug Exondys 51 (eteplirsen) buoyed many in this research space, but last night we were all reminded of how tough this disease area can be after Catabasis posted disappointing data for its candidate edasalonexent.
Just months after writing off a cholesterol drug, Catabasis is back with the first data on its Duchenne muscular dystrophy candidate.
Catabasis has suffered its first big setback in the clinic, writing off its midstage program for CAT-2054 in hypercholesterolemia after its trial flopped and sent its shares into a tailspin.